FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509560382> ?p ?o ?g. }

• W2509560382 abstract "In Cambodia, elimination of artemisinin resistance through direct elimination of the Plasmodium falciparum parasite may be the only strategy. Prevalence and incidence at district and village levels were assessed in Chey Saen district, Preah Vihear province, North of Cambodia. Molecular and clinical indicators for artemisinin resistance were documented. A cross sectional prevalence survey was conducted at village level in the district of Chey Saen from September to October 2014. Plasmodium spp. was assessed with high volume quantitative real-time polymerase chain reaction (qPCR). Plasmodium falciparum-positive samples were screened for mutations in the k13-propeller domain gene. Treatment effectiveness was established after 28 days (D28) using the same qPCR technique. Data from the provincial surveillance system targeting symptomatic cases, supported by Médecins Sans Frontières (MSF), were used to assess incidence. District P. falciparum prevalence was of 0.74 % [0.41; 1.21]; village prevalence ranged from 0 to 4.6 % [1.4; 10.5]. The annual incidence of P. falciparum was 16.8 cases per 1000 inhabitants in the district; village incidence ranged from 1.3 to 54.9 for 1000 inhabitants. Two geographical clusters with high number of cases were identified by both approaches. The marker for artemisinin resistance was found in six samples out of the 11 tested (55 %). 34.9 % of qPCR blood analysis of symptomatic patients were still positive at D28. The overall low prevalence of P. falciparum was confirmed in Chey Saen district in Cambodia, while there were important variations between villages. Symptomatic cases had a different pattern and were likely acquired outside the villages. It illustrates the importance of prevalence surveys in targeting interventions for elimination. Mutations in the k13-propeller domain gene (C580Y), conferring artemisinin resistance, were highly prevalent in both symptomatic and asymptomatic cases (realizing the absolute figures remain low). Asymptomatic individuals could be an additional reservoir for artemisinin resistance. The low effectiveness of dihydroartemisinin–piperaquine (DHA–PPQ) for symptomatic cases indicates that PPQ is no longer able to complement the reduced potency of DHA to treat falciparum malaria and highlights the need for an alternative first-line treatment." @default.
• W2509560382 created "2016-09-16" @default.
• W2509560382 creator A5007491309 @default.
• W2509560382 creator A5011576395 @default.
• W2509560382 creator A5026319565 @default.
• W2509560382 creator A5029859369 @default.
• W2509560382 creator A5032394349 @default.
• W2509560382 creator A5051408897 @default.
• W2509560382 creator A5053039253 @default.
• W2509560382 creator A5074220181 @default.
• W2509560382 creator A5080741366 @default.
• W2509560382 date "2016-09-01" @default.
• W2509560382 modified "2023-10-12" @default.
• W2509560382 title "Assessing the asymptomatic reservoir and dihydroartemisinin–piperaquine effectiveness in a low transmission setting threatened by artemisinin resistant Plasmodium falciparum" @default.
• W2509560382 cites W1948311135 @default.
• W2509560382 cites W2040713555 @default.
• W2509560382 cites W2055971230 @default.
• W2509560382 cites W2062863104 @default.
• W2509560382 cites W2063909986 @default.
• W2509560382 cites W2108523891 @default.
• W2509560382 cites W2124634096 @default.
• W2509560382 cites W2125005430 @default.
• W2509560382 cites W2126591359 @default.
• W2509560382 cites W2135697415 @default.
• W2509560382 cites W2139324809 @default.
• W2509560382 cites W2154998673 @default.
• W2509560382 cites W2161311583 @default.
• W2509560382 cites W2165691527 @default.
• W2509560382 cites W2169329132 @default.
• W2509560382 cites W2171102256 @default.
• W2509560382 cites W2229864756 @default.
• W2509560382 cites W2303652270 @default.
• W2509560382 cites W4255691240 @default.
• W2509560382 doi "https://doi.org/10.1186/s12936-016-1487-z" @default.
• W2509560382 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5009552" @default.
• W2509560382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27585957" @default.
• W2509560382 hasPublicationYear "2016" @default.
• W2509560382 type Work @default.
• W2509560382 sameAs 2509560382 @default.
• W2509560382 citedByCount "8" @default.
• W2509560382 countsByYear W25095603822017 @default.
• W2509560382 countsByYear W25095603822018 @default.
• W2509560382 countsByYear W25095603822020 @default.
• W2509560382 crossrefType "journal-article" @default.
• W2509560382 hasAuthorship W2509560382A5007491309 @default.
• W2509560382 hasAuthorship W2509560382A5011576395 @default.
• W2509560382 hasAuthorship W2509560382A5026319565 @default.
• W2509560382 hasAuthorship W2509560382A5029859369 @default.
• W2509560382 hasAuthorship W2509560382A5032394349 @default.
• W2509560382 hasAuthorship W2509560382A5051408897 @default.
• W2509560382 hasAuthorship W2509560382A5053039253 @default.
• W2509560382 hasAuthorship W2509560382A5074220181 @default.
• W2509560382 hasAuthorship W2509560382A5080741366 @default.
• W2509560382 hasBestOaLocation W25095603821 @default.
• W2509560382 hasConcept C120665830 @default.
• W2509560382 hasConcept C121332964 @default.
• W2509560382 hasConcept C142724271 @default.
• W2509560382 hasConcept C190612196 @default.
• W2509560382 hasConcept C203014093 @default.
• W2509560382 hasConcept C2776120307 @default.
• W2509560382 hasConcept C2777616469 @default.
• W2509560382 hasConcept C2778048844 @default.
• W2509560382 hasConcept C2778371730 @default.
• W2509560382 hasConcept C2781160685 @default.
• W2509560382 hasConcept C42972112 @default.
• W2509560382 hasConcept C61511704 @default.
• W2509560382 hasConcept C71924100 @default.
• W2509560382 hasConcept C99454951 @default.
• W2509560382 hasConceptScore W2509560382C120665830 @default.
• W2509560382 hasConceptScore W2509560382C121332964 @default.
• W2509560382 hasConceptScore W2509560382C142724271 @default.
• W2509560382 hasConceptScore W2509560382C190612196 @default.
• W2509560382 hasConceptScore W2509560382C203014093 @default.
• W2509560382 hasConceptScore W2509560382C2776120307 @default.
• W2509560382 hasConceptScore W2509560382C2777616469 @default.
• W2509560382 hasConceptScore W2509560382C2778048844 @default.
• W2509560382 hasConceptScore W2509560382C2778371730 @default.
• W2509560382 hasConceptScore W2509560382C2781160685 @default.
• W2509560382 hasConceptScore W2509560382C42972112 @default.
• W2509560382 hasConceptScore W2509560382C61511704 @default.
• W2509560382 hasConceptScore W2509560382C71924100 @default.
• W2509560382 hasConceptScore W2509560382C99454951 @default.
• W2509560382 hasFunder F4320310331 @default.
• W2509560382 hasIssue "1" @default.
• W2509560382 hasLocation W25095603821 @default.
• W2509560382 hasLocation W25095603822 @default.
• W2509560382 hasLocation W25095603823 @default.
• W2509560382 hasLocation W25095603824 @default.
• W2509560382 hasOpenAccess W2509560382 @default.
• W2509560382 hasPrimaryLocation W25095603821 @default.
• W2509560382 hasRelatedWork W2052130859 @default.
• W2509560382 hasRelatedWork W2145094277 @default.
• W2509560382 hasRelatedWork W2151531806 @default.
• W2509560382 hasRelatedWork W2171450360 @default.
• W2509560382 hasRelatedWork W2344672766 @default.
• W2509560382 hasRelatedWork W2613173822 @default.
• W2509560382 hasRelatedWork W2790415871 @default.
• W2509560382 hasRelatedWork W3120168175 @default.
• W2509560382 hasRelatedWork W4210932539 @default.
• W2509560382 hasRelatedWork W4293707105 @default.

• next